COMING SOON! 50 + KEY INDUSTRY EXPERT SPEAKERS
RICHARD JONES
Patient Engagement Managing Director
Leader and patient expert in multi-award winning, research led, patient engagement and health technology business. Richard is a highly successful, commercially astute leader and problem solver with a proven track record in senior roles in the pharmaceutical industry and healthcare agencies. Richard combines 20 years’ knowledge from GSK, AstraZeneca and Pfizer with 10 years specialist agency experience. This unrivalled pedigree enables Richard to quickly understand his client’s business and offer innovative, differentiated and effective solutions. A senior executive, comfortable at operating strategically, above practice and respected by C-level customers. Richard has a passion for crystallising issues on patient engagement and developing innovative and effective solutions.
Alan J. Balch, PhD.
CEO
Dr. Balch has over twenty years of executive leadership in the non-profit sector with an emphasis on consensus-building and collaboration. He has led numerous federal advocacy efforts on a range of issues both at the legislative and regulatory level. He became the CEO of both NPAF and PAF in 2013. From 2006 - 2013, he served as the Vice President of the Preventive Health Partnership -- a national health promotion collaboration between the American Cancer Society, American Diabetes Association, and
American Heart Association. Prior to 2006 Dr. Balch was the Executive Director of Friends of Cancer Research.Dr. Balch has served on the Executive Board of the Patient Advocate Foundation and National Patient Advocate Foundation since 2007. He also serves on numerous advisory boards and committees. He earned his PhD in environmental studies with a concentration in political economy in 2003 from the University of California, Santa Cruz; master’s degree in environmental sciences in 1997 from the University of Texas in San Antonio; his bachelor’s degree (cum laude) in biology in 1994 from Trinity University in San Antonio.
Tricia Mullins
Global Head, Patient Advocacy
Tricia Mullins is the Global Head, Patient Advocacy at Atara Bio, with 20 years of experience working in patient advocacy, medical affairs and commercial operations globally. She has held key leadership roles of increasing responsibility over her career and has extensive experience bringing novel therapies to market, launching 10 unique products, 5 in the ultra-rare space. Tricia holds a Bachelor of Science in Business and Communications from St. John’s University and is pursuing her Master’s in Public Health. In her spare time, Tricia serves as Co-Chair of the Board of Directors at the Neuromuscular Disease Foundation (NDF), a non-profit organization, for those living with GNE Myopathy, an ultra-rare condition. Tricia also serves as an ongoing mentor to advocates in the rare disease community. Tricia is passionate about patients, advocacy, and access, bringing new innovative solutions to companies, patient organizations, patients and their families living with rare, chronic, and life-threatening conditions.
Wendy Erler
VP Patient Advocacy STAR & LEAP
Wendy has built her patient advocacy career in many rare disease communities and oncology. Wendy Erler is the VicePresident of Patient Experience, STAR and Advocacy at AstraZeneca in Alexion’s rare disease, where she is responsible for leading the enterprise innovation model to gather and incorporate patient insights throughout the drug development and commercialization processes. She leads the Global PatientAdvocacy function and has responsibility the rare disease patient advocacy team.Previously, Ms. Erler was on the executive leadership team at Wave LifeSciences where she led Patient Advocacy and Commercial. Wendy graduated from Miami University and earned her MBA from St. Joseph’s University.
Judith L. Campagnari
Executive Director, Head, Global Patient Insights and Solutions (GPIS)
Alexion Pharmaceuticals
Judith L. Campagnari
Executive Director, Head, Global Patient Insights and Solutions (GPIS)
Judy Campagnari, MBA is Executive Director, Head of Alexion’s Global Patient Insights and Solutions (GPIS). She leads a team of innovators who partner with patients and other external stakeholders to create solutions and strategies to support decision-making related to the company’s drug development and commercial activities, thus creating beneficial change for people living with rare diseases. Judy has more than 25 years in the pharmaceutical industry and is a pharmaceutical strategist with proven experience creating “value from vision”. She has extensive experience developing strategic commercial plans for candidates from the pre-clinical/discovery phase through proof of concept. She has broad therapeutic & disease area expertise including rare disease, neurology, metabolic diseases, bone diseases, gastrointestinal diseases, immunology, and oncology. Judy has a bachelor’s degree from Smith College (Northampton, MA), an MBA from the Katz Graduate School of Business (University of Pittsburgh), and an Executive MBA Certificate from the Harvard Business School.
Kalahn Taylor-Clark, PhD, MPH
VP and Head of Strategic Partnerships and Innovation
Kalahn Taylor-Clark, PhD, MPH is Vice President and Head of Strategic Partnerships and Innovation at Myovant Sciences. In this capacity she oversees patient centered advocacy and digital innovation. Her team is responsible for driving transformative advocacy in the areas of women’s health and prostate cancer, addressing health equity, and advancing digital innovation strategies to improve patient experiences and outcomes.Prior to this post Dr. Taylor-Clark served as the Global Head of Patient Centered Outcomes and Innovation at Sanofi. In this post, she served as the strategic patient lead to global business units in the US/EU, China and Emerging Markets, across all therapeutic areas of the company. Taylor-Clark’s work helped the company to develop, measure, amplify and adapt solutions based on key stakeholder input (e.g. patient advocacy groups, scientific societies and community-based organizations).Dr. Taylor-Clark also served as a Senior Advisor to the Center for Health Policy, Research and Ethics and Assistant Professor in Health Administration and Policy at George Mason University, where she provided strategic guidance on the development and evaluation of patient and consumer engagement activities for a range of stakeholders, including: private and public payers, hospital and integrated health systems, business groups, and policy leaders. Previously, she served as the Director of Health Policy at the National Partnership for Women and Families, where her primary responsibilities were in providing strategic direction on a range of activities related to delivery system and payment reform, including: quality measurement, reduction of health disparities, patient and consumer engagement in patient-centered care delivery and the effective use of health information technology (HIT) to improve patient-reported outcomes measurement. From 2007-2011, Dr. Taylor-Clark led the Patient-Centeredness and Health Equity Portfolios in the Engelberg Center for Health Care Reform at the Brookings Institution in Washington D.C.She holds a BA in International Relations from Tufts University, an MPH from Tufts School of Medicine, and a PhD in Health Policy from Harvard University. She serves as a Member of the Board of Trustees for Tufts University, and as President of the Board of Directors at Prevention Institute in Oakland, CA. Dr. Taylor-Clark is an adjunct professor at the Carey School of Business at Johns Hopkins University. Dr. Taylor-Clark has also lived in Japan, Ghana and France, and is proficient in French.
Tom Croce
Vice President, Global Patient Advocacy
Coming Soon! Available Shortly.
MARIANNE GANDEE
VP, Patient Solutions & Alliances
Coming Soon! Available Shortly.
TEONNA WOOLFORD
Chief Executive Officer
Teonna Woolford was born and raised in Baltimore Maryland. She has always been talkative, friendly, and full of life. She has Sickle Cell Anemia SS and has faced numerous health complications as a result. A true fighter at heart, she has recovered from numerous complications including bilateral hip replacements, a failed bone marrow transplant, many pain crises, and several other complications. She has a zeal for effecting change throughout the Sickle Cell community and understands the realities of those impacted by the disease. While sickle cell has been a huge part of Teonna’s life, she does her best not to let sickle cell define who she is. Teonna has been blessed to sit at some incredible tables and contributed to publications and working committees with the American Society of Hematology and NHLBI. She is also the founder and CEO of a new nonprofit organization, The Sickle Cell Reproductive Health Education Directive.
Ginger Davis
President
Teresa Ginger Davis Biography.Teresa Ginger Davis has been a life-long health and education advocate, and spokesperson for sickle cell disease. She has more than 25-years of experience in the health industry.Prior to starting her development and communications consultancy UNTOLD Story LLC in 2016, she was an allied healthcare professional – working as a genetic councilor, health educator and advocate. Davis has participated in developing national health policy with organizations like NYMAC (NY-Mid Atlantic Genetics Council), and the NYS
Sickle Cell Advisory Consortium. As the former Director of Outreach and Development of the Sickle Cell Thalassemia Patients Network (SCTPN) she created, implemented, and coordinated the organization’s public education program activities, in addition to implementing a diversified fundraising program.Through SCTPN, Ms. Davis applied her biology and naturopathic health education towards working with eighteen New York City hospitals on HRSA grants to deliver care coordination and transitions services for pediatric hematology clients and their families, also care coordination and referral to needed services for adults lost to care after transitioning from pediatrics.SCTPN is one of four NE CBOs to be awarded the HRSA Newborn Screening Follow-Up multiyear grant, and is the lead CBO for the NYS Health & Hospital Services Collective
Impact Initiative to End the Stigma Against Sickle Cell Disease. Ginger is now leading SCTPN as its newly elected president.Her two top priorities for the next 3-years is to:1. Driving the organization’s expansion statewide by establishing affiliates and
chapters in Staten Island, Long Island, Albany, Buffalo, Rochester and Syracuse; and2. Collaborate with other sickle cell organizations to increase public education and
testing for sickle cell trait (SCT) in the northeast region.
Frank Rivera
Co-Founder/President
Founder/President- Sarcoidosis of Long Island
Advocate, Navigator and Mentor - Foundation for Sarcoidosis Research
February 2015- Accommodation for President Barack Obama
Frank Rivera is a two time published author:
An autobiography called "Walking in Silent Pain"
A continuation biography "I Have Sarcoidosis but it Doesn't Have Me", a book about Strength and Resilience.
December 2017 Frank was named People of the Year in the newspaper organization TBR News Media.
April 2018, Frank was interviewed by NBC Nightly News about the “Right To Try” bill.
2020- 2021- Organized 4 Online Forums.
Worked with a group of Sarcoidosis doctors, researchers and patients to have a medical journal published by NIH: https://pubmed.ncbi.nlm.nih.gov/34203584/https://www.strongerthansarcoidosis.org/
Barby Ingle
President
Barby Ingle is a best-selling author, reality personality, and lives with multiple rare and chronic diseases; reflex sympathetic dystrophy (RSD), migralepsy, PALB2-var breast cancer, valley fever, endometriosis and other pain disorders. Barby is a chronic pain educator, patient advocate, and president of the International Pain Foundation. She is also a motivational speaker and best-selling author on pain topics. Her blog, reality shows and media appearances are used as a platform to help her become an e-Patient advocate, and she presents at healthcare conferences, speaking publicly, sharing her story, educating and advocating for patients across the globe. She has received more than 20 accommodations over the years for her advocacy work .
www.internationalpain.org
Neena Neezar
Founder & Executive Director
Dr. Nizar serves as Founder and Executive Director of the Jansen’s Foundation. She is a rare disease advocate and Change Leader in the rare disease community, specifically in the field of ultra-rare skeletal dysplasias. Dr. Nizar has a Doctoral degree in Educational Leadership from Creighton University, Nebraska, is a TEDx speaker, a blogger and passionate voice for the special needs community. She is a Trailblazer for the Rare Advocacy Movement (RAM) and Nebraska’s Mother of The Year, 2018. Dr. Nizar is also a rare disease patient and a mother to two boys with Jansen’s Metaphyseal Chondrodysplasia – a disease that affects less than 30 people worldwide.
Behtash Bahador
Associate Director
Behtash Bahador is an Associate Director at the non-profit organization CISCRP, and holds a Master of Science in Health Communication from the Tufts University School of Medicine. Since 2014, he has collaborated with a range of stakeholder groups to establish and implement patient- and public-centric initiatives across the life-cycle of drug and treatment development. This has included supporting the development of regulatory and cross-disciplinary best practice guidelines, operationalizing key elements of evidence-based public health programming into research engagement activities, and always keeping the needs of patients, participants and the public at the forefront of his work.
Christine Von Raesfeld
Founder & CEO
Christine Von Raesfeld is a leader in bringing a critically needed patient perspective to cutting edge medical innovations. Committed to providing patients with chronic and rare diseases with the support they need, Christine works with patient advocacy organizations, industry representatives, and individual patients and their loved ones. Living with many rare and chronic diseases, she believes that in order to foster understanding and empowerment, patients must be treated as people first. As a patient involved in Stanford's Humanwide program, she speaks on the benefits and advantages of precision medicine, with a special interest in pharmacogenomics.Christine’s drive to make lives better for patients has been nationally recognized. In 2019, she spoke on stage at the Startup Health Festival as an invited guest of Sanguine Biosciences. In 2018, Christine served on the Team of Patient Advisors for PatientsLikeMe. She was also recognized as a Wego Health 2018 Top 10 Healthcare Collaborators Patient Leader as well as named one of Silicon Valley Business Journal's 100 Women of Influence for 2019.Christine’s conference speaking engagements, consulting efforts, and ability to share her personal experiences have allowed her to bring a much-needed change to the healthcare industry while bridging the gap between biopharmaceutical and patient stakeholders.https://www.peoplewithempathy.org/
Khrystal Davis
Founder
Khrystal joined the rare disease community in 2011 when her newborn son, Hunter, was diagnosed with Spinal Muscular Atrophy (SMA) Type 1, the leading genetic cause of mortality in children under the age of two. SMA Type 1, often described as ALS in babies, robs the ability to move, swallow, and ultimately breathe. Khrystal is the author of Hunt for a Cure: An Unexpected Adventure to Save a Life. Khrystal founded Zebra Leaf Publishing to provide the rare disease community a platform to promote rare disease awareness.In May of 2016, Khrystal advocated alongside the FAST Movement (Families for the Acceleration of Spinal Muscular Atrophy Treatments) in a meeting with top FDA representatives for access to Spinraza, an SMA treatment in clinical trials at the time. Together with other FAST members, she asked the FDA to stop placebo trials, provide a means of access for the weakest SMA patients, accelerate the approval, and approve the treatment for all SMA patients regardless of age or type of SMA. In an interim look completed on August 1, 2016, the FDA found the treatment met trial objectives. An Expanded Access Program for SMA Type 1 patients commenced August 12, 2016, and the FDA approved Spinraza for children and adults with SMA on December 23, 2016. Khrystal is committed to improving health outcomes in those with rare diseases through improved access to rare disease treatments. She advocates for the expansion of newborn screening programs and insurance policies that conform to FDA labels for orphan drugs. She is a proponent of patient-driven access to rare disease treatments.Khrystal holds a Juris Doctorate from Stetson University College of Law and is certified in Clinical Trial Design and Interpretation by Johns Hopkins through the Coursera program. She is a proud wife and mother of five who enjoys traveling the world with her family.http://txrare.org/
EMILY PARKS
Founder
Coming Soon! Available Shortly.
Cheya Pope
Vice President of Corporate Affairs & Patient Advocacy
Cheya Pope is Vice President of Corporate Affairs & Patient Advocacy for Epizyme, where she is responsible for the company’s communications initiatives, including traditional and social media, product communications, corporate visibility and thought leadership activities, disease awareness initiatives, patient advocacy, internal communications, and corporate social responsibility efforts. Prior to joining Epizyme, Cheya held positions of increasing responsibility in Corporate Affairs and Patient Advocacy for companies including Intercept Pharmaceuticals, Sanofi Global Oncology, Genomic Health, and Genentech. In these roles, she led the outreach to global non-profit cancer and rare disease organizations and patient communities, and provided counsel to internal stakeholders on key advocacy issues. Cheya has dedicated her career to working in healthcare communications and patient advocacy, and she graduated Phi Beta Kappa from the University of California at Davis with a BA in English.
Jocelyn Duff
Co-Founder/Executive Director
Jocelyn Duff is the Executive Director and Co-founder of CureCMT4J, an all-volunteer non-profit dedicated to expediting a treatment or cure for Charcot Marie Tooth Disease Type 4J (CMT4J). Jocelyn and her husband, John, founded CureCMT4J in June, 2016 after receiving a diagnosis of CMT4J for their daughter, Talia, following a six-year diagnostic odyssey. CMT4J is a severe, progressive, inherited neuromuscular disease often compared to ALS.At present there is no treatment or cure. In its initial 18 months of operation, CureCMT4J gathered world experts in CMT4J/FIG4 and gene therapy, raised over $1 million, and funded pre-clinicalwork at the Jackson Laboratory, establishing efficacy using gene therapy in CMT4J mouse models. A first-in-human gene therapy clinical trial is planned for 2020.A physician assistant (PA) by training, Jocelyn has worked in Family Practice and Internal Medicine for over 20 years. Duff was a recipient of The Science Channel’s “Superheroes in Science” award, in June, 2017. Jocelyn was selected to speak at The Atlantic’s “Women in Science” symposium in Washington, D.C., discussing breakthroughs in science, and at Harvard’s 2018 “Precision Medicine” conference.Jocelyn strives to connect other rare families with researchers and to assist them in expediting treatments. Jocelyn enjoys spending time outdoors with her husband and two amazing daughters.
Lisa Deck
Founder and Director
Lisa Deck is a Founder & Director of Sisters@Heart, a non-profit organization that improves the lives of those affected by heart disease and stroke. Lisa is a former Go Red for Women NationalSpokeswomen for the American Heart Association and currently serves as an Advocacy Board Member for the American Heart Association in Boston and Southern New England.Suffering her first three strokes twenty years ago, Lisa has been a patient activist and international speaker for the past two decades. Lisa lobbies at the local, state and Federal level for health and awareness policy development . She is a widely known advocate voice that inspires others and raises awareness of heart disease, stroke and Moyamoya disease.In 2015, Lisa was diagnosed with Moyamoya Disease, a rare cerebrovascular disease, after an 18-year diagnostic odyssey. She underwent two brain bypass surgeries to restore blood flow to her brain. Since then, Lisa has become actively involved in rare disease advocacy, serving as a Committee member of Rare New England. Rare New England brings together New England patients, families and providers touched by rare and complex disorders. On behalf of Rare New England, Lisa produces and hosts a local cable show, The World of Rare Disease. Lisa is also active with the newly formed Moyamoya Foundation. Lisa lives in North Attleboro, MA with her husband and two children.
Kristof Vanfraechem,
Founder & CEO
Coming Soon! Available Shortly.
Mark Doyle
Director
Mark Doyle is co-founder of The Method, a British learning and development company offering innovative training programmes to effect behaviour change. Using his background as a professional actor and entrepreneur, Mark creates emotional connections with audiences by upending traditional learning methods and developing immersive experiences involving actors, multimedia materials, physical items and even artificial intelligence delivered via a smartphone app.Mark works alongside fellow co-founder and writer John Keates, and leads the company’s award-winning, flagship programme, A Life in a Day. Created out of a desire to support greater patient-centric care and engagement within healthcare, A Life in a Day aims to help the pharmaceutical and healthcare industries understand the challenges and choices faced by patients every day. The experiences are designed to evoke an emotional response, inspiring those who take part to become more aware of patients’ needs and consider how they can make a lasting, positive change.A Life in a Day has so far been delivered successfully in more than 55 countries to audiences as diverse as healthcare professionals, pharmaceutical employees, politicians and patient support groups.Mark is an energising and sought-after speaker on the subjects of understanding patients’ needs and changing behaviour.
Molly MacDonald
Founder, CEO
Molly MacDonald knows what it’s like to battle the financial burdens of breast cancer while undergoing treatment to battle the disease.
Diagnosed with early stage breast cancer in April 2005, the disease was unlikely to take her life, but did take her livelihood. She was between jobs and was unable to start her new job as planned. Her family’s already tight budget was immediately overburdened with the addition of monthly COBRA health insurance payments coupled with the loss of her income. Within months, MacDonald and her family faced the potential for catastrophic financial losses, including the loss of their home. At the end of treatment when family and friends stopped delivering dinner, MacDonald was forced to use a local food bank to feed her family. When MacDonald’s quest to Get Help was met with blank stares, she became determined to Give Help to others suffering from lost income as a result of their diagnosis and treatment.
In 2006 she founded The Pink Fund, which provides 90 days of non-medical financial aid to cover basic cost of living expenses, such as health insurance, housing, transportation and utilities. By providing this financial bridge, The Pink Fund helps to meet basic needs, while decreasing stress levels. These factors improve treatment adherence, improving survivorship outcomes and quality of
life. Since its founding through October 2022 The Pink Fund has made over $6.4 million in bill payments on behalf of breast cancer survivors in active treatment.
In 2012, Ford Motor Company invited The Pink Fund to be one of their charity partners benefiting from the Warriors in Pink program which allowed them to serve patients in all 50 states. For her work, MacDonald has been the recipient of many local and national awards. Most recently she was named to the 2020 George H. W. Bush Points of Light Inspiration Honor Roll, Crain’s 2020
Notable Women in Health, and a 2020 AARP Purpose Prize Fellow. In 2019, EyeforPharma named her Patient Champion North America. In March 2018, MacDonald was awarded NAWBO Detroit’s Philanthropic Award and named a 2018 Healthcare Hero by Crain’s Detroit Business. Ernst & Young named her a Finalist for the EY Entrepreneur of the Year for Michigan and Northwest
Ohio in 2016 and 2017.
She is a 2014 Pink Power Mom, awarded by Kids II and Bright Starts, and a 2014 Purpose Prize Fellow, presented by Encore.org for her “outstanding contributions toward solving the world’s most challenging problems in the second half of life” and Money Magazine’s 2014 Michigan Money Hero.
A long-time columnist for Breast Cancer Wellness Magazine focusing on financial wellness, she is a contributing writer to the American Journal of Managed Care and a member of the Advisory Board for V-Bid, Value Based Insurance Design at The University of Michigan.
The Pink Fund was a finalist, recognized as a top global cancer innovator in patient centric care by the LIVESTRONG Foundation’s inaugural Big C Competition, for its work in helping to rebuild financial health. In 2014 and 2015 The Pink Fund was named by Time and Money, together with Charity Navigator, as one of five national breast cancer charities worthy of your donation, where
you can feel confident your dollars will be put to good use.
A passionate Patient Advocate, MacDonald is a thought leader in the breast cancer space, specifically in cancer related financial toxicity. She is a sought after keynote speaker sharing her personal struggles which led to the founding of The Pink Fund while advocating for improved patient care.
MacDonald is a graduate from The University of Michigan with a degree in journalism and has extensive work experience in journalism, public relations, marketing and sales. She is a Goldman Sachs Alumni Scholar, graduating in August 2022 from the program.
A mother of five adult children, and grandmother to two grandchildren, she is happily married to Tom Pettit, best known as Tom Terrific.
JASON R CRITES
Founder & CEO
Jason Crites is the Founder/CEO of Assurance Health Data (AHD), a Chicago based health technology company that has created the trusted third-party health data platform and marketplace. After his father's aggressive late-stage prostate cancer and his nephew's rare Leigh's Syndrome diagnosis, Jason became obsessed with solving the problems researchers face in obtaining and sharing data. After 18 years at IBM where he was one of the creators of the federated data model and the global storage solution – closing over a billion in deals and optimizing the data infrastructure of many of the Fortune 500 – he founded AHD with the mission to make health data liquid.
HEIDI FLOYD
Patient Experience SME
Coming Soon! Available Shortly.
JOHN DALY
Head & VP, Patient Services Immunology & Enterprise Marketing
Coming Soon!
Ambre Minty
Founder, Living with Dys
Ambre is a mom, advocate, and writer. She has written about her journey with chronic illness, feeding tubes, and home parenteral nutrition (HPN) on her blog, “Living with Dysautonomia.” She has received several WEGO Health Nominations, for both her blog, Living with Dys, and her work in advocacy.Ambre has advocated for better education regarding both home enteral and parenteral nutrition (HPEN). She is a vocal advocate for more discussion, and dialogue of self esteem, and body image issues some struggle with within the chronic illness community. She is a fierce advocate of breaking the mold, and empowering others to see their worth and beauty. She has participated in photoshoots to help promote/encourage body positivity for those with medical devices, & chronic illness. She also strives to break the taboo blocks of mental health discussion in chronic illness. Her dedication, hope and motivation led her to create Chronically Strong, a program within Living With Dys. Where she will strive to give hope, encourage and empower others to see themselves beyond their diagnosis, and to have hope for a future.https://livingwithdys.com
LORIANA HERNANDEZ-ALDAMA,
2x Survivor, Advocate, Author, Educator, Founder
Coming Soon!
SARAH KRÜG
CEO
Sarah Krüg is the CEO of CANCER101, a patient advocacy organization, whose mission is to empower patients and their families to navigate their cancer care and partner with their healthcare team to make informed decisions. Sarah is also founder of the Health Collaboratory, a global innovation hub that's built on the foundation of advancing health equity, understanding the impact of behavior science, and cultivating trust by amplifying the voice of the patient, care partner and clinician in the co-design of the future of healthcare. The Health Collaboratory has launched various innovations such as Prescription to Learn®, a Health GPS, and the Patient Shark Tank®, among others that have been co-designed with patients. Through the Patient Shark Tank ®, over 25,000 patients and care partners across disease states have evaluated/partnered on innovations across the globe, including technology, education, research, and policy. The Health Collaboratory is comprised of a network of >300 subject matter experts.Sarah is on the board and past president of the Society for Participatory Medicine, a patient: clinician member driven organization, whose mission is to enable collaborative partnerships between patients and healthcare professionals. She was also on the board of the National Organization for Rare Disorders. Sarah is the author of “A Roadmap to Wellness” with another book “Health Confessions” to launch in 1Q23. She is a global speaker and recently gave a TEDx talk called “The Patient: Doctor Tango”.She previously held the position of Global Education Director, as well as Patient Advocacy Lead at Pfizer. She also established the Global Investigator Initiated Research Program at Pfizer. Prior to joining Pfizer, Sarah spearheaded the development of the Disease Management Clinical Pathways and conducted clinical research at Memorial Sloan- Kettering Cancer Center.
PAULA ORANDASH
Patient Engagement Liaison
Paula has amassed her entire career in health care services helping families with rare disease, where her focus has been in neuromuscular disease. Before joining PTC, she spent 26 years in patient services at the Muscular Dystrophy Association (MDA). Her current role at PTC in Patient Engagement enables her to ensure families have a personal connection with PTC. She has developed an educational platform, called Insightful Moments, on behalf of patients and families ensuring they have access to education and support.
Ramita Tandon
Chief Clinical Trials Officer
As the Chief Clinical Trials Officer at Walgreens, Ramita Tandon is responsible for leading and driving growth for the Company’s new clinical trials business. In her role, Ramita works across the healthcare and life sciences industries to enable next-generation clinical trials so that breakthrough treatments reach patients faster. Her team is focused on unlocking value and improving access, awareness and trust by efficiently matching diverse patient populations to sponsor-led trials, reducing trial operational complexities and patient burdens, as well as capitalizing on Walgreens deep patient insights and leveraging real-world data from owned and partner assets.Ramita brings more than 25 years of leadership and operational experience across a portfolio of industry-leading businesses and services in real-world evidence and patient-centered health outcomes. Prior to joining Walgreens, she served as the Chief Operating Officer at Trio Health, and prior to that she was the Executive Vice President, Commercialization and Outcomes at ICON.As a transformational leader, Ramita is passionate in her belief that a best-in-class operating model employing insights and innovation can deliver gains in operations and forge stronger connections with all stakeholders, including biopharmaceutical companies, healthcare systems and payers. Ramita has recently been named to Drug Store News’ Top Women in Health, Wellness & Beauty class of 2022 for Business Excellence, Fierce Healthcare’s 2022 Women of Influence and listed in the 2018 PharmaVOICE 100.Ramita is an internationally recognized speaker and author whose focus is on how to bridge the gap between commercial and clinical development. She is a graduate of the University of Michigan and the Boston University School of Public Health.
JULIETTE CHEN
Global Evidence and Outcomes Leader
Coming Soon! Available Shortly.
Carolina Consuegra,
Co-Founder, Marketing & Strategy Director,
Coming Soon! Available Shortly.
Available Shortly
VP & Head of Patient Centric Affairs
Coming Soon!
Available Shortly
Head of Patient Engagement
Coming Soon! Available Shortly.
Available Shortly
VP Clinical Trials
Coming Soon! Available Shortly.